CLINICAL EXPERIENCE OF THE USE OF PD-1 INHIBITOR IN PATIENTS WITH NON-CELL LUNG CANCER WITH METASTATIC DAMAGE OF KIDNEYS AND ADRENALS
Ksenya A. Sarantseva , D. I Yudin , M. A Okruzhnova , K. P Laktionov
Russian Journal of Oncology ›› 2017, Vol. 22 ›› Issue (5) : 250 -254.
CLINICAL EXPERIENCE OF THE USE OF PD-1 INHIBITOR IN PATIENTS WITH NON-CELL LUNG CANCER WITH METASTATIC DAMAGE OF KIDNEYS AND ADRENALS
Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. A new promising direction of NSCLC treatment in the second line is the use of immunotherapy by inhibitors of immune control points. This group of drugs radically changed the outlook on the prognosis of patients with disseminated NSCLC progressing on previous platinum-containing chemotherapy. The article presents the results of a clinical trial program for nivolumab and the analysis of clinical cases of its application in NSCLC patients with metastatic damage of the kidneys and adrenal glands.
NSCLC / control point inhibitors / immunotherapy
| [1] |
Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015; 65(1): 5-29. |
| [2] |
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населения России в 2014 г. M.; 2015. |
| [3] |
NCCN Guidelines Version 2016. |
| [4] |
Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. J.A.M.A. 2004; 292(4): 470-84. |
| [5] |
Argiris A., Schiller J.H. Can current treatments for advanced non-small-cell lung cancer be improved? J.A.M.A. 2004; 292(4): 499-500. |
| [6] |
Переводчикова Н.И. Химиотерапия немелкоклеточного рака легкого - состояние проблемы в 2000 г. Практическая онкология. 2000; 3: 29-37. |
| [7] |
Кондратьев В.Б., Карасева Н.А. Лечение и профилактика осложнений химиотерапии препаратами платины и таксанами. Практическая онкология. 2000; 3: 38-42. |
| [8] |
Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005; (4): 307-20. |
| [9] |
Cosaert J., Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br. J. Cancer. 2002; 87(8): 825-33. |
| [10] |
Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003; (5): 460-4. |
| [11] |
Pasetto L.M., D’Andrea M.R., Brandes A.A., Rossi E., Monfardini S. The development of platinum compounds and their possible combination. Crit. Rev. Oncol. Hematol. 2006; (1): 59-75. |
| [12] |
Chan B.A., Hughes B.G. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl. Lung Cancer Res. 2015; (1): 36-54. |
| [13] |
Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Пперегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016; (3): 17-24. |
| [14] |
Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 373(2): 123-35. |
| [15] |
Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 373(17): 1627-39. |
| [16] |
Юдин Д.И., Лактионов К.П., Саранцева К.А., Черненко П.А., Арзуманян А.Л. Системы критериев оценки ответа солидных опухолей при лечении иммуноонкологическими препаратами. Злокачественные опухоли. 2017;(1):42-6. |
| [17] |
Реутова Е.В., Лактионов К.П., Бредер В.В., Саранцева К.А., Окружнова М.А., Перегудова М.В. Иммуноопосредованные нежелательные явления, связанные с лечением препаратами, блокирующими контрольные точки Т-лимфоцитов. Злокачественные опухоли. 2016; (4): 68-76. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
